Physician profile
Dorothy E Stege
NPI 1174532493
$722.43
in general payments reported to CMS, 2019-2025
11 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.38 · 2022: $164 · 2023: $162 · 2024: $190 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $201.41 | 2021-2024 | Rexulti |
| Abbvie INC. | $162.18 | 2022-2024 | Vraylar |
| Novo Nordisk INC | $68.21 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Mylan Specialty L.P. | $57.27 | 2021-2024 | Yupelri |
| Amgen INC. | $56.83 | 2021-2025 | Evenity, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.30 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $36.23 | 2024-2025 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $31.35 | 2022 | |
| Exact Sciences Corporation | $28.85 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $21.73 | 2024 | Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Stege listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.